Tirzepatide is a dual GIP and GLP-1 receptor agonist. Where semaglutide works on one receptor, tirzepatide engages two, each tied to a hormone involved in fullness and blood sugar control. For people in the Los Angeles area, it is the medication behind Bodi Envi's Personalized Compounded Tirzepatide Weight-Management Programs.
The compounded form is prepared by a licensed compounding pharmacy for one named patient, on the strength of that patient's prescription. Dosing follows a plan the licensed provider set: a weekly injection, beginning at the dose the provider chooses and changing only when the provider decides it should.
Personalized Compounded Tirzepatide is not FDA-approved and is not equivalent to the FDA-approved products that contain the same active ingredient, Mounjaro® and Zepbound®. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, which is why a licensed provider decides case by case whether treatment is appropriate. Brand names are trademarks of their respective owners. Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.